Scarica l'app Stockscreener
33.96
1.37%
0.46
Dopo l'orario di chiusura:
34.01
0.05
+0.15%
Precedente Chiudi:
$33.50
Aprire:
$33.02
Volume 24 ore:
991.98K
Relative Volume:
1.07
Capitalizzazione di mercato:
$3.28B
Reddito:
$225.27M
Utile/perdita netta:
$-140.06M
Rapporto P/E:
-21.26
EPS:
-1.5974
Flusso di cassa netto:
$-87.93M
1 W Prestazione:
-4.26%
1M Prestazione:
-11.15%
6M Prestazione:
+16.94%
1 anno Prestazione:
+2.32%
Intervallo 1D:
$32.80
$34.28
Intervallo di 1 settimana:
$32.34
$36.35
Portata 52W:
$26.81
$42.68
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
33.96 | 3.28B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
529.69 | 134.26B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.16 | 85.50B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.27 | 83.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.76 | 56.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.36 | 42.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-16 | Iniziato | William Blair | Outperform |
| 2026-10-14 | Ripresa | Stifel | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 4 Ideaya Biosciences Inc For: 8 October By Investing.com - Investing.com Nigeria
Idea Biosciences president and CEO Yujiro Hata sells $985k in shares - Investing.com
Form 4 Ideaya Biosciences Inc For: 8 October By Investing.com - Investing.com India
Form 4 Ideaya Biosciences Inc For: 8 October By Investing.com - Investing.com UK
Option exercises are part of a CEO's proposed share sale at IDEAYA (Nasdaq: IDYA). - Stock Titan
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development - Yahoo Finance
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Santa Maria Times
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
IDEAYA Biosciences (Nasdaq:IDYA)Stock Analysis - Simply Wall Street
IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth - Investing.com Canada
IDYA: NDA submission, ESMO data, and Roche collaborations set the stage for major oncology advances - TradingView
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com Canada
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com India
IDEAYA Biosciences Doses First Patient in Phase 3 Trial - grafa.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data - Investing.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data By Investing.com - Investing.com Canada
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PR Newswire
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo Finance
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Nigeria
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Canada
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com India
Phase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race - BioWorld News
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Nigeria
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - 富途牛牛
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress - Investing.com
IDEAYA Biosciences Sets London R&D Day for Nov. 16 | IDYA Stock News - Stock Titan
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - Yahoo Finance
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - PR Newswire
IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849 DLL3 TOP1 ADC On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer - marketscreener.com
IDEAYA Biosciences (IDYA) Slips 2.3% to $40.81 as Biotech Momentum FadesMomentum Factor - vinanet.vn
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Morningstar
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Nigeria
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Australia
Ideaya Biosciences stock hits 52-week high at 40.88 USD - Investing.com
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Canada
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com UK
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
IDEAYA (IDYA) Close: Adds 1.43% to Close at $39.67 at the Close; Technical Setup: the Near-Term Reference Band Stretches From $37.69 to $41.65 in the Available RecordFloat Adjusted Cap - vinanet.vn
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ideaya Biosciences Inc Azioni (IDYA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hata Yujiro S | President and CEO |
Oct 06 '26 |
Sale |
37.41 |
26,338 |
985,397 |
690,695 |
| YUJIRO HATA | CEO |
Oct 06 '26 |
Proposed Sale |
38.23 |
230,316 |
8,804,981 |
0 |
| Ruiz Briseno Andres | Chief Accounting Officer |
Jul 07 '26 |
Sale |
40.01 |
9,550 |
382,131 |
26,466 |
| Andres Ruiz Briseno | Senior VP |
Jul 07 '26 |
Proposed Sale |
40.01 |
9,550 |
382,131 |
0 |
| Ruiz Briseno Andres | Chief Accounting Officer |
Jul 07 '26 |
Option Exercise |
12.86 |
9,550 |
122,813 |
36,016 |
| Stein Jeffrey | Director |
Mar 02 '26 |
Buy |
32.96 |
50,000 |
1,647,890 |
54,281 |
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):